Phlebology June 2020 PMID 31510866

Deep vein sclerosis following sclerotherapy: Ultrasonic and d-dimer criteria.

Kurosh Parsi, Brydon Panozzo, Alison Bull, Anes Yang, Mina Kang, Yana Parsi, David E Connor

Full text PDF Download social card

Mentions

Peak: 6 in Nov 2024

across 2 sources since Oct 2019

Extended reach

4,736

potential audience

Total likes

Video views

4,005

Mentions per month

Oct 2019 – Nov 2024

Where it's discussed

YouTube6 videos
X / Twitter1 posts

AI synopsis

What people are saying

The discussion reflects a moderate level of interest and engagement, as seen in posts asking for explanations, such as 'What does it mean post treatment,' and referencing expert opinions like Prof Parsi, indicating a desire to understand the clinical significance of deep vein sclerosis after procedures. The tone is inquisitive and educational, emphasizing a professional interest in clarifying complex concepts.

AgreementNeither agree nor disagree

The discussion largely seeks clarification and understanding rather than outright disagreement or full agreement.

InterestModerate interest

Participants show moderate interest, mainly curious about the implications of deep vein sclerosis post-treatment.

EngagementModerate engagement

Comments suggest some engagement through asking questions and highlighting expert commentary.

ImpactNeutral impact

The conversation's overall impact appears limited, focusing more on clarification than on influencing practice or opinion.

Abstract in brief

This study investigates deep vein sclerosis caused by sclerotherapy and explores how ddimer levels can help differentiate it from deep vein thrombosis (DVT).
Ultrasound and ddimer tests were used to identify cases of deep vein occlusion over six years, revealing that certain ddimer thresholds are more associated with sclerosis versus thrombosis.
Findings suggest that lower sclerosant concentrations and higher foam volumes increase the risk of deep vein occlusion, with most patients showing good recanalisation rates and no major thromboembolic complications.

Read the full abstract